查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837113

經導管肺動脈瓣市場（按瓣膜類型、應用和最終用戶分類）—2025-2032 年全球預測

Transcatheter Pulmonary Valve Market by Valve Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，經導管肺動脈瓣市場規模將成長至 1.5,169 億美元，複合年成長率為 10.19%。

主要市場統計數據
基準年2024年 6976萬美元
預計2025年 7676萬美元
預測年份：2032年 1.5169億美元
複合年成長率（%） 10.19%

經導管肺動脈瓣治療的全面介紹，重點介紹臨床進展、手術實踐以及對相關人員的策略意義

經導管肺動脈瓣置換術已從一項實驗性治療轉變為臨床可行的治療方案，解決了先天性和後天性右心室流出道功能障礙患者中尚未滿足的重大醫療需求。經皮肺動脈瓣系統的經皮使臨床醫生能夠提供一種比重複開胸手術創傷更小的治療方案，從而降低手術全期併發症發生率，並縮短兒童和成人先天性心臟病患者的康復路徑。手術技術的改進、影像學的進步以及對患者選擇標準的更深入理解，改善了經導管肺動脈瓣置換術的療效，並擴大了其臨床適應症。

如今，臨床實踐強調心臟團隊合作，整合先天性心臟疾病專家、介入科醫生、心臟外科醫生和高級影像專家。這種多學科方法最佳化了器材選擇、介入策略和術後監測。隨著手術操作經驗的累積以及機構對患者追蹤路徑的規範化，該手術的安全性已得到改善，同時對有症狀和無症狀性病變的治療閾值也得到了改善。監管部門的批准和真實世界註冊數據進一步使經導管肺動脈瓣介入治療合法化，促進了其在三級轉診中心和部分門診手術中心的廣泛應用。

從策略角度來看，設備製造商、醫療系統和臨床研究人員應致力於將技術進步轉化為可擴展的醫療模式。未來，需要在培訓、上市後證據產生和供應鏈韌性方面進行協調一致的投資，以確保不同地區和不同醫療服務提供者都能平等地獲得治療並取得一致的治療結果。

對改變肺瓣膜護理和提供者策略的技術、臨床和操作變化的權威概述

在技​​術、臨床和操作動態融合的推動下，肺動脈瓣治療領域正在經歷一場變革性轉變。瓣膜設計的進步，包括改進的徑向力分佈、組織工程和輸送系統的靈活性，正在擴大其解剖學適用性並減少入路挑戰。增強的顯像模式和融合引導平台能夠在複雜的右心室流出道中實現精確的定位和尺寸測量，從而降低併發症率，並增強操作者對先前被認為是高風險的解剖區域的信心。

同時，隨著瓣膜的長期耐久性和患者生活品質成為核心終點，臨床模式正在轉變。器械可回收性和模組化方法的創新，支持針對不同患者群體的分階段手術和個人化治療。監管生態系統正在適應混合證據模型，該模型將隨機數據與高品質的註冊研究相結合，從而加快了在未滿足需求最大的領域獲得有條件核准。付款人對基於價值的指標（例如降低再入院率、縮短住院時間以及改善長期功能）的興趣日益濃厚。

在營運方面，卓越中心正在組建，以整合專業知識並簡化患者診療路徑，同時設備開發人員和影像處理公司聯盟正在整合預測規劃工具。因此，競爭格局正在從單一產品策略轉向整合設備、影像通訊協定和臨床培訓的整合解決方案——重新定義高價值經導管肺部治療的意義。

清楚分析 2025 年美國關稅變化將如何重塑心臟設備領域的供應鏈、採購經濟和戰略製造決策。

美國將於2025年實施新關稅，這為設備製造商和醫療保健提供者重新評估其供應鏈、採購和定價策略提供了一個獨特的視角。對進口零件和組裝設備徵收的關稅將影響採購的經濟性，迫使製造商評估本地生產、近岸外包選項和其他採購方式，以保護淨利率並維持與醫院採購商的競爭性定價。對於依賴全球供應網路的組織而言，此類保護主義措施可能會增加前置作業時間和交易成本，從而加劇對多方採購和庫存緩衝的需求。

臨床項目和醫院採購負責人將面臨修改合約條款的談判，這些條款將考慮進口相關附加稅和設備供應的潛在變化。衛生系統必須在控制成本的必要性和優先考慮患者治療結果的臨床需求之間取得平衡。這通常需要臨床負責人和採購團隊之間進行透明的對話，就可接受的權衡取捨以及高風險患者的優先用藥問題進行溝通。同時，製造商正在加快努力，實現零件供應商多元化，提升國內供應商的資質，並投資自動化製造，以抵銷關稅帶來的成本壓力。

政策反應和籌資策略最終將決定關稅在多大程度上改變醫療器材的採用軌跡。積極主動地模擬關稅敏感性和應急生產能力，並向付款人和醫療系統採購方清晰地傳達臨床價值的利益相關人員，將最有能力緩解2025年帶來的營運中斷。這種適應性態勢將降低患者風險，並保持創新和更廣泛臨床應用的勢頭。

醫療設備、臨床和最終用戶細分揭示了產品特性和患者需求的交匯點，從而塑造了商業性和臨床路徑

精細的細分框架揭示了臨床需求、產品差異化和最終用戶行為在製定策略時相互交織的因素。根據瓣膜類型，市場主要分為兩種：球囊擴張型和自擴張式瓣膜。球囊擴張型瓣膜包括 Melody 瓣膜和 Sapien 經導管瓣膜等成熟平台，這些平台已被證明效用於特定尺寸和導管結構的瓣膜。自擴張式瓣膜系統，以 Harmony 經導管肺動脈瓣膜和 Venus P 瓣膜等技術為代表，具有良好的順應性和徑向適應性，適用於範圍更廣且通常不規則的右心室流出道。這些瓣膜類型之間的技術權衡體現在各中心的臨床選擇標準、庫存管理和訓練要求。

基於應用的細分進一步細化了臨床路徑和證據需求。患者情況多種多樣，包括複雜病症、肺動脈瓣逆流和肺動脈瓣狹窄，每種情況都有不同的動態考量和手術規劃需求。針對混合病症的設備必須在密封、錨定和動態性能方面表現出多功能性，而主要針對狹窄或逆流的設備可以分別進行最佳化，以實現Low profile輸送和增強徑向支撐。門診手術中心、心臟中心和醫院各自擁有獨特的基礎設施、病例組合和採購模式。門診手術中心優先考慮吞吐量和當日出院通訊協定，心臟中心強調複雜病例和多學科路徑，而醫院則在急性護理能力和廣泛的住院能力之間取得平衡。

了解瓣膜類型、臨床應用和最終用戶環境如何相互作用，使製造商和供應商能夠根據設備採用和結果監測的實際情況調整產品系列、培訓計劃和商業化計劃。

簡潔的區域概述，比較全球主要地區的採用趨勢、法規環境和商業化路徑

區域動態在塑造可及性、監管途徑和商業化執行方面發揮核心作用。在美洲，成熟的卓越中心和介入性心臟病學生態系統，加上強大的臨床網路和完善的報銷框架，為先進經導管肺動脈介入治療方案的早期應用創造了有利環境。該地區的市場准入和規模化發展得益於高手術量、集中的專業知識以及活躍的臨床研究團隊，這些團隊能夠產生上市後的安全性和性能數據。

歐洲、中東和非洲地區（EMEA）市場競爭激烈，監管環境、報銷途徑和基礎設施差距各不相同，這些因素都會影響其採用率。西方市場通常在臨床證據支持療效改善的情況下能夠快速採用，而更廣泛的電子病歷 (EMR) 市場和新興非洲市場則優先考慮經濟高效的解決方案和彈性供應鏈。這些地區的策略合作夥伴通常需要定價、能力建構專案和本地證據產生來推動採用。

亞太地區對先天性和結構性心臟疾病計畫的投資正在加速，其戰略重點是國內製造和創新中心。該地區的一些國家正在擴大心臟專科中心的規模，並推廣區域臨床登記，以指導適合特定族群解剖結構的器材。隨著製造商不斷探索監管途徑和當地臨床預期，跨境合作和技術轉移也日益普遍。

對競爭定位、聯盟策略和創新重點領域的深入概述，這些領域塑造了肺部瓣膜護理領域的公司級差異化

經導管肺動脈瓣的競爭格局由成熟的心血管器材製造商和敏捷的專業創新者所構成。領先的公司優先考慮一種平衡的方法，將器械工程與臨床證據生成和醫療保健提供者教育相結合。器械製造商與先進成像公司之間的合作日益普遍，從而能夠提供更可靠的術前規劃和術中指導。與契約製造和材料科學公司建立策略聯盟也增強了製造的擴充性和組件的品管。

創新管線強調耐用性、可交付性和對複雜解剖結構的適應性，越來越多的參與企業正在探索組織治療和抗鈣化技術，以延長瓣膜壽命。商業策略著重於提供配套服務，包括量角器、模擬訓練和結果支持，以縮短新用戶的學習曲線。與此同時，一些公司正在透過區域分銷商和臨床合作夥伴關係進行有針對性的地域擴張，而另一些公司則在監管和報銷條件有利於高階定位的情況下，投資直接進入市場。

合併、收購和授權協議仍然是實現品類領先地位的策略性槓桿，尤其是在能夠整合互補的影像、供應鏈和報銷專業知識的情況下。將強大的臨床項目與可擴展的生產和清晰的價值通訊相結合的組織，將最有可能獲得持續的臨床吸引力和機構採用。

為臨床、製造和商業領導者提供可行的建議，以加速採用、確保供應彈性並展示差異化的臨床價值

產業領導者應採取積極的策略，協調臨床、商業和營運重點，以實現經導管肺動脈瓣治療的長期價值。投資於產生嚴格的上市後證據，包括基於註冊的療效和真實世界績效指標，為付款人和轉診中心建立令人信服的臨床敘述。將對臨床數據的承諾與模組化培訓計劃和基於模擬的監考相結合，將加速該療法的採用，同時確保患者安全和一致的療效。

在營運方面，我們將實現零件採購多元化，並盡可能地進行近岸外包，以減輕關稅影響並確保供應的連續性。我們將及早與監管機構溝通，明確設備的改進路徑，並利用前瞻性隊列和實用性註冊數據制定適應性證據計劃。在商業方面，我們將針對終端用戶細分市場，最佳化價值主張，例如，為門診手術中心提供吞吐量和成本提案，為心臟病中心提供先進的病例支持和多學科夥伴關係，以及為醫院提供全面的圍手術全期護理方案。

最後，我們將與影像和數位醫療服務提供者建立策略合作夥伴關係，提供整合的規劃工具，以減少診療流程的差異性。透過優先採用透明的定價模式和與結果掛鉤的契約，使獎勵與醫療系統和付款人保持一致，我們將在保障淨利率和確保永續成長的同時，支持更廣泛的醫療服務可及性。

透明、多方法的研究途徑結合了臨床訪談、監管調查、供應鏈分析和資料三角測量，確保獲得可靠、可行的見解

本報告所採用的研究將一手資料、二手資料和結構化資料檢驗結合。主要方法包括對介入性心臟病專家、先天性心臟外科醫生、採購負責人和行業高管進行深入訪談，以收集關於器械選擇、操作流程和應用障礙的經驗性見解。此外，我們還對同行評審的臨床文獻、監管部門的核准、臨床註冊摘要以及特定器械的安全溝通進行了結構化審查，以確保與最新的臨床證據和安全訊號保持一致。

採用資料三角測量法來協調現場訪談、臨床報告和官方監管文件之間的差異，並強調資訊來源的可重複性和透明度。製造和供應鏈評估利用組件映射、供應商訪談和公開的貿易數據來識別風險的關鍵節點和潛在的緩解途徑。分析框架結合了定性輸入的主題編碼、政策和關稅影響的情境分析以及比較設備特性矩陣，以突出差異化因素。

品質保證包括由臨床和市場分析師進行的多階段同行評審、對主要來源引文的檢驗以及敏感性檢查，以確保結論能夠適應區域實踐模式和監管時間表的差異。我們承認存在一些局限性，包括不同註冊機構的臨床報告標準存在差異，以及不斷變化的政策環境，這些因素可能會隨著時間的推移改變採購和報銷的動態。

簡潔的結論強調了臨床證據、供應彈性和策略商業化的一致性，這是永續採用和對患者產生影響的先決條件。

經導管肺動脈瓣治療正處於曲折點，技術創新、臨床證據和策略商業化必須協調一致，才能實現永續的患者獲益和永續的推廣應用。改良的瓣膜設計、先進的影像技術和不斷發展的治療模式，拓展了經皮肺動脈瓣置換術的臨床潛力。然而，營運方面的挑戰，包括供應鏈彈性、關稅壓力以及對令人信服的真實世界證據的需求，仍然是決定推廣速度和公平性的關鍵因素。

對於在該領域制定策略的相關人員來說，當務之急顯而易見：投資於持久的臨床證據，確保多元化的製造地，並根據門診中心、心臟專科計畫和醫院系統的具體需求定製商業化方案。將這些要素與彈性價格設定框架和全面的培訓相結合的組織，將最有能力將臨床前景轉化為持續的患者可及性和長期價值創造。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對高手術風險的兒童和成人患者的微創經導管肺動脈瓣植入手術激增
  • 擴大經導管肺動脈瓣治療先天性右心室流出道功能障礙的適應症
  • 利用先進的影像導引和3D列印技術，擴大採用個人化瓣膜尺寸
  • 國內製造商的不斷增加推動了新興市場價格的下降和本土閥門的推出
  • 將生物可吸收材料整合到經導管肺動脈瓣設計中，以最大限度地減少長期併發症
  • 正在進行臨床試驗以評估新型經導管肺動脈瓣的長期血流動力學性能和安全性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 經導管肺動脈瓣市場（依瓣膜類型）

  • 球囊擴張閥
    • 旋律閥
    • SAPIEN經導管瓣膜
  • 自膨脹閥
    • Harmony經導管肺動脈瓣
    • 維納斯 P 閥

9. 經導管肺動脈瓣市場（依應用）

  • 複雜病變
  • 肺逆流症
  • 肺動脈狹窄

10. 經導管肺動脈瓣市場（依最終用戶）

  • 門診手術中心
  • 心臟中心
  • 醫院

11. 經導管肺動脈瓣市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 12 章。按組別分類的經導管肺動脈瓣市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 經導管肺動脈瓣市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic plc
    • Venus MedTech（Hangzhou）Co., Ltd.
    • TaeWoong Medical Industrial Co., Ltd.
    • Xeltis SA
    • Lifetech Scientific Corporation
    • Lepu Medical Technology（Beijing）Co., Ltd.
    • MicroPort Scientific Corporation
    • Umbra Valve Technologies BV
    • Jude Medical Inc
    • Braile Biomedica
Product Code: MRR-03168519576D

The Transcatheter Pulmonary Valve Market is projected to grow by USD 151.69 million at a CAGR of 10.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 69.76 million
Estimated Year [2025] USD 76.76 million
Forecast Year [2032] USD 151.69 million
CAGR (%) 10.19%

A comprehensive introduction to transcatheter pulmonary valve therapy highlighting clinical evolution, procedural adoption, and strategic implications for stakeholders

Transcatheter pulmonary valve therapy has transitioned from an experimental intervention into a clinically viable option that addresses significant unmet needs among patients with congenital and acquired right ventricular outflow tract dysfunction. The introduction of percutaneous valve systems has enabled clinicians to offer less invasive alternatives to repeat open-heart surgery, reducing perioperative morbidity and shortening recovery pathways for both pediatric and adult congenital populations. Procedural refinements, imaging advances, and a deeper understanding of patient selection criteria have collectively strengthened outcomes and expanded the clinical indications for catheter-based pulmonary valve replacement.

Clinical practice now emphasizes heart-team collaboration that integrates congenital cardiologists, interventionalists, cardiac surgeons, and advanced imaging specialists. This multidisciplinary approach optimizes device selection, access strategy, and post-procedural surveillance. As operators accumulate procedural experience and centers codify pathways for patient follow-up, safety profiles have improved while the threshold for treating symptomatic and asymptomatic lesions has evolved. Regulatory clearances and real-world registry data have further legitimized transcatheter pulmonary valve interventions, fostering broader adoption across tertiary referral centers and select ambulatory surgical settings.

From a strategic perspective, device manufacturers, health systems, and clinical investigators are positioned to translate technical advances into scalable care models. The pathway forward requires coordinated investments in training, post-market evidence generation, and supply chain resilience to ensure equitable access and consistent procedural performance across geographies and provider types.

An authoritative synthesis of the transformative technological, clinical, and operational shifts reshaping pulmonary valve therapy and provider strategy

The landscape for pulmonary valve therapies is undergoing transformative shifts driven by converging technological, clinical, and operational dynamics. Advances in valve design, including improvements in radial force profiles, tissue engineering, and delivery-system flexibility, are expanding anatomical applicability and reducing access-related challenges. Enhanced imaging modalities and fusion-guidance platforms enable precise positioning and sizing in complex right ventricular outflow tracts, lowering complication rates and expanding operator confidence in anatomies previously deemed high risk.

Concurrently, a shift in clinical paradigms has emerged as long-term valve durability and patient quality of life become central endpoints. Innovations in device retrievability and modular approaches support staged procedures and tailored therapies for diverse patient cohorts. Regulatory ecosystems are adapting to hybrid evidence models that combine randomized data with high-quality registries, accelerating conditional approvals in regions where unmet need is highest. Reimbursement conversations are likewise evolving, with payers increasingly attentive to value-based metrics such as reduced readmissions, shorter length of stay, and long-term functional improvement.

Operationally, centers of excellence are forming to concentrate expertise and streamline patient pathways, while partnerships between device developers and imaging firms are integrating predictive planning tools. As a result, the competitive landscape is shifting from single-product strategies to integrated solutions that bundle devices, imaging protocols, and clinical training, thereby redefining what it means to deliver high-value transcatheter pulmonary care.

A clear analysis of how the 2025 United States tariff changes are reshaping supply chains, procurement economics, and strategic manufacturing decisions in cardiac device sectors

The implementation of new tariff measures in the United States in 2025 has introduced a tangible lens through which device manufacturers and health providers are re-evaluating supply chain, procurement, and pricing strategies. Tariffs on imported components and assembled devices affect procurement economics, prompting manufacturers to assess localized production, nearshoring options, and alternative sourcing to preserve margin and maintain competitive pricing for hospital purchasers. These protective trade measures can increase lead times and transactional costs for organizations reliant on global supply networks, reinforcing the need for multi-sourcing and inventory buffers.

Clinical programs and hospital purchasers face the prospect of negotiating revised contract terms that account for import-related surcharges and potential variability in device availability. Health systems must balance the imperative of cost containment with clinical imperatives that prioritize patient outcomes; this often necessitates transparent dialogues between clinical leaders and procurement teams to align on acceptable trade-offs and priority access for high-risk patients. In parallel, manufacturers are accelerating efforts to diversify component suppliers, qualify domestic vendors, and invest in automated manufacturing to offset tariff-driven cost pressures.

Policy responses and procurement strategies will ultimately determine the extent to which tariffs alter device adoption trajectories. Stakeholders that proactively model tariff sensitivities, secure contingency manufacturing capacity, and communicate clinical value compellingly to payers and health system buyers will most effectively mitigate the operational disruptions introduced in 2025. This adaptive posture reduces risk to patients and preserves momentum for innovation and broader clinical adoption.

A strategic breakdown of device, clinical, and end-user segmentation revealing where product features and patient needs intersect to shape commercial and clinical pathways

A granular segmentation framework illuminates where clinical demand, product differentiation, and end-user behavior intersect to shape strategy. Based on valve type, the landscape is characterized by two dominant device approaches: balloon expandable designs and self-expanding systems. Balloon expandable valves include well-established platforms such as the Melody valve and the Sapien transcatheter valve, which have proven utility in specific valve sizes and conduit anatomies. Self-expanding systems are represented by technologies like the Harmony transcatheter pulmonary valve and the Venus P-Valve, which offer conformability and radial adaptation suited to broader and often irregular right ventricular outflow tracts. The technical trade-offs between these valve types inform clinical selection criteria, inventory management, and training requirements across centers.

Application-based segmentation further refines clinical pathways and evidence needs. Patient presentations span combined lesions, pulmonary regurgitation, and pulmonary stenosis, each with distinct hemodynamic considerations and procedural planning imperatives. Devices compatible with mixed pathology must demonstrate versatility in sealing, anchoring, and hemodynamic performance, while those intended primarily for stenosis or regurgitation can optimize for low-profile delivery or enhanced radial support, respectively. End-user segmentation underscores where adoption manifests operationally: ambulatory surgical centers, cardiac centers, and hospitals each have unique infrastructure, case mix, and purchasing models. Ambulatory surgical centers may prioritize throughput and same-day discharge protocols, cardiac centers focus on complex cases and multidisciplinary pathways, and hospitals balance acute care capacity with broader inpatient capabilities.

Understanding how valve type, clinical application, and end-user environment interact enables manufacturers and providers to align product portfolios, training programs, and commercialization plans with the practical realities of device deployment and outcomes monitoring.

A concise regional intelligence overview that contrasts adoption dynamics, regulatory environments, and commercialization pathways across key global territories

Regional dynamics play a central role in shaping access, regulatory pathways, and commercial execution. In the Americas, established centers of excellence and a mature interventional cardiology ecosystem create a favorable environment for early adoption of advanced transcatheter pulmonary solutions, supported by robust clinical networks and well-developed reimbursement frameworks. Market entry and scale-up efforts in this region benefit from high procedural volumes, concentrated specialist expertise, and active clinical research communities that generate post-market safety and performance data.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory diversity, variable reimbursement pathways, and disparate infrastructure influence adoption rates. Western European markets typically demonstrate rapid uptake when clinical evidence supports improved outcomes, whereas emerging markets in the broader EMR and African corridors prioritize cost-effective solutions and resilient supply chains. Strategic partners in these geographies often require tailored pricing, capacity-building programs, and local evidence generation to facilitate uptake.

Asia-Pacific exhibits accelerated investment in congenital and structural heart disease programs alongside a strategic emphasis on domestic manufacturing and innovation hubs. Several countries in this region are scaling specialized cardiac centers and driving localized clinical registries that inform device adaptation for population-specific anatomies. Cross-border collaboration and technology transfer initiatives are increasingly common as manufacturers navigate regulatory pathways and local clinical expectations.

An incisive overview of competitive positioning, alliance strategies, and innovation focus areas shaping company-level differentiation in pulmonary valve therapies

The competitive environment in transcatheter pulmonary valves reflects a mix of established cardiovascular device manufacturers and agile specialized innovators. Leading organizations prioritize a balanced approach that couples device engineering with clinical evidence generation and provider education. Partnerships between device makers and advanced imaging firms are becoming commonplace, enabling more reliable pre-procedure planning and intra-procedural guidance. Strategic collaborations with contract manufacturers and material science firms also enhance manufacturing scalability and component quality control.

Innovation pipelines emphasize durability, deliverability, and adaptability to challenging anatomies, with an increasing number of entrants exploring tissue treatments and anti-calcification technologies to extend valve longevity. Commercial strategies focus on bundled service offerings that include proctoring, simulation training, and outcomes support to reduce the learning curve for new adopters. In parallel, some companies are pursuing targeted geographic expansion through local distributors and clinical partnerships, while others invest in direct-market presence where regulatory and reimbursement conditions favor premium positioning.

Mergers, acquisitions, and licensing agreements continue to be strategic levers for achieving category leadership, particularly where complementary imaging, supply chain, or reimbursement expertise can be integrated. Organizations that align robust clinical programs with scalable manufacturing and clear value messaging are best positioned to capture sustained clinical traction and institutional adoption.

Actionable recommendations for clinical, manufacturing, and commercial leaders to accelerate adoption, secure supply resilience, and demonstrate differentiated clinical value

Industry leaders should pursue a proactive strategy that aligns clinical, commercial, and operational priorities to capture long-term value in transcatheter pulmonary valve care. Invest in rigorous post-market evidence generation that includes registry-based outcomes and real-world performance metrics to build a compelling clinical narrative for payers and referral centers. Combine these clinical data efforts with modular training programs and simulation-based proctoring to accelerate adoption while maintaining patient safety and consistent procedural outcomes.

From an operational standpoint, diversify component sourcing and pursue nearshoring where feasible to mitigate tariff exposure and ensure continuity of supply. Engage early with regulatory bodies to clarify pathways for incremental device enhancements and to design adaptive evidence plans that leverage both prospective cohorts and pragmatic registry data. On the commercial front, craft value propositions tailored to end-user segments: emphasize throughput and cost-efficiency for ambulatory surgical facilities, advanced case support and multidisciplinary partnerships for cardiac centers, and comprehensive perioperative care bundles for hospitals.

Finally, pursue strategic collaborations with imaging and digital-health providers to deliver integrated planning tools that reduce procedural variability. Prioritize transparent pricing models and outcomes-linked contracting to align incentives with health systems and payers, thereby supporting broader access while protecting margin and ensuring sustainable growth.

A transparent, multi-method research approach combining clinical interviews, regulatory review, supply-chain analysis, and data triangulation to ensure robust, actionable insights

The research underpinning this report blends primary qualitative engagement with rigorous secondary synthesis and structured data validation. Primary methods included in-depth interviews with interventional cardiologists, congenital heart surgeons, procurement leaders, and industry executives to capture experiential insights on device selection, procedural workflows, and adoption barriers. These conversations were complemented by structured reviews of peer-reviewed clinical literature, regulatory approvals, clinical registry summaries, and device-specific safety communications to ensure alignment with the latest clinical evidence and safety signals.

Data triangulation was applied to reconcile discrepancies between field interviews, clinical reports, and public regulatory documentation, with a focus on reproducibility and source transparency. Manufacturing and supply-chain assessments utilized component mapping, supplier interviews, and publicly available trade data to identify critical nodes of risk and potential mitigation pathways. The analytical framework incorporated thematic coding of qualitative input, scenario analysis for policy and tariff impacts, and comparative device feature matrices to surface differentiators.

Quality assurance included multi-level peer review by clinical and market analysts, verification of primary source citations, and sensitivity checks to ensure conclusions remain robust given variations in regional practice patterns and regulatory timelines. Limitations are acknowledged, including variability in clinical reporting standards across registries and evolving policy environments that may alter procurement and reimbursement dynamics over time.

A concise conclusion emphasizing the alignment of clinical evidence, supply resilience, and strategic commercialization as prerequisites for sustainable adoption and patient impact

Transcatheter pulmonary valve therapy stands at an inflection point where technical innovation, clinical evidence, and strategic commercialization must align to achieve durable patient benefit and sustainable adoption. The confluence of improved valve designs, advanced imaging, and evolving treatment paradigms has expanded the clinical promise of percutaneous pulmonary valve replacement. However, operational challenges such as supply-chain resilience, tariff pressures, and the need for convincing real-world evidence remain critical determinants of the pace and equity of adoption.

For stakeholders crafting strategy in this space, the imperative is clear: invest in durable clinical evidence, secure diversified manufacturing footprints, and tailor commercialization approaches to the specific needs of ambulatory centers, cardiac specialty programs, and hospital systems. Organizations that integrate these elements with flexible pricing frameworks and comprehensive training will be best placed to convert clinical promise into consistent patient access and long-term value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in minimally invasive transcatheter pulmonary valve implantations for high surgical risk pediatric and adult patients
  • 5.2. Introduction of next generation self-expanding transcatheter pulmonary valves with enhanced durability and reduced reintervention rates
  • 5.3. Expansion of transcatheter pulmonary valve indications to treat native right ventricular outflow tract dysfunction
  • 5.4. Growing adoption of advanced imaging guidance and three dimensional printing for personalized valve sizing
  • 5.5. Rising presence of domestic manufacturers driving price reductions and regional valve launches in emerging markets
  • 5.6. Integration of bioresorbable materials into transcatheter pulmonary valve design to minimize long term complications
  • 5.7. Ongoing clinical trials assessing long term hemodynamic performance and safety of novel transcatheter pulmonary valves

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Pulmonary Valve Market, by Valve Type

  • 8.1. Balloon Expandable Valve
    • 8.1.1. Melody Valve
    • 8.1.2. Sapien Transcatheter Valve
  • 8.2. Self Expanding Valve
    • 8.2.1. Harmony Transcatheter Pulmonary Valve
    • 8.2.2. Venus P-Valve

9. Transcatheter Pulmonary Valve Market, by Application

  • 9.1. Combined Lesions
  • 9.2. Pulmonary Regurgitation
  • 9.3. Pulmonary Stenosis

10. Transcatheter Pulmonary Valve Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals

11. Transcatheter Pulmonary Valve Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Transcatheter Pulmonary Valve Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Transcatheter Pulmonary Valve Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Medtronic plc
    • 14.3.2. Venus MedTech (Hangzhou) Co., Ltd.
    • 14.3.3. TaeWoong Medical Industrial Co., Ltd.
    • 14.3.4. Xeltis SA
    • 14.3.5. Lifetech Scientific Corporation
    • 14.3.6. Lepu Medical Technology (Beijing) Co., Ltd.
    • 14.3.7. MicroPort Scientific Corporation
    • 14.3.8. Umbra Valve Technologies B.V.
    • 14.3.9. Jude Medical Inc
    • 14.3.10. Braile Biomedica

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. TRANSCATHETER PULMONARY VALVE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. TRANSCATHETER PULMONARY VALVE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSCATHETER PULMONARY VALVE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 91. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 97. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 106. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 108. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 118. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 154. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 192. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 204. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 205. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 206. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 207. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 228. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 240. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 241. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 242. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 243. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 245. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 252. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 253. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 254. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 255. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 265. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 274. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 275. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 276. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 277. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 284. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 285. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 286. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 287. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. MEXICO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2025-2032 (USD MILLION)
  • TABLE 295. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2024 (USD MILLION)
  • TABLE 296. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2025-2032 (USD MILLION)
  • TABLE 297. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM TRANSCATHETER PULMONARY VALVE MARKET SIZ